Analysis of microdissected prostate tissue with ProteinChip arrays--a way to new insights into carcinogenesis and to diagnostic tools.
Prostate carcinomas are one of the most common malignancies in western societies. The pathogenesis of this tumor is still poorly understood. These tumors present with two characteristic features: epithelial-mesenchymal interactions, which play a pivotal role for tumor development and most of clinically manifest cancers arise in prostate proper compared to a minority of tumors which develop in the transitional zone. Deciphering the epithelial-mesenchymal cross talk and identification of molecular pecularities of the sub-populations of cells in different zones can therefore help understanding carcinogenesis and development of new, non-invasive tools for the diagnosis and prognosis of prostate carcinomas which has remained a challenge until today. A ProteinChip array technology (SELDI = surface enhanced laser desorption ionization) has been developed recently by Ciphergen Biosystems enabling analysis and profiling of complex protein mixtures from a few cells. This study describes the analysis of approximately 500-1000 freshly obtained prostate cells by SELDI-TOF-MS (surface enhanced laser desorption ionization time-of-flight mass spectrometry). Pure cell populations of stroma, epithelium and tumor cells were selected by laser assisted microdissection. Multiple specific protein patterns were reproducibly detected in the range from 1.5 to 30 kDa in 28 sub-populations of 4 tumorous prostates and 1 control. A specific 4.3 kDa peak was increased in the prostate tumor stroma compared to normal prostate proper and transitional zone stroma and increased in prostate tumor glands compared to normal prostate proper and transitional zone glands. Coupling laser assisted microdissection with SELDI provides tremendous opportunities to identify cell and tumor specific proteins to understand molecular events underlying prostate carcinoma development. It underlines the vast potential of this technology to better understand pathogenesis and identify potential candidates for new specific biomarkers in general which could help to screen for and distinguish disease entities, i.e. between clinically significant and insignificant carcinomas of the prostate.
Wellmann
Axel
A
Institute of Pathology, University of Bonn, D-53127 Bonn, Germany. axel.wellmann@uni.bonn.de
Wollscheid
Volker
V
Lu
Hong
H
Ma
Zhan Lu
ZL
Albers
Peter
P
Schütze
Karin
K
Rohde
Volker
V
Behrens
Peter
P
Dreschers
Stefan
S
Ko
Yon
Y
Wernert
Nicolas
N
D000368:Aged; D015415:Biomarkers; D006801:Humans; D053685:Laser Therapy; D008297:Male; D013058:Mass Spectrometry / Q000379:methods*; D008875:Middle Aged; D011467:Prostate / Q000378:metabolism* / Q000648:ultrastructure; D011471:Prostatic Neoplasms / Q000175:diagnosis / Q000378:metabolism* / Q000648:ultrastructure; D011506:Proteins / Q000032:analysis*
D015415:Biomarkers; D011506:Proteins